325 related articles for article (PubMed ID: 18237245)
1. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
2. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
3. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
Yu CP; Yu JC; Sun CA; Tzao C; Ho JY; Yen AM
Breast Cancer Res Treat; 2008 Jan; 107(1):95-102. PubMed ID: 18043898
[TBL] [Abstract][Full Text] [Related]
4. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer and cyclin D1 gene polymorphism in Turkish women.
Yaylim-Eraltan I; Ergen A; Görmüs U; Arikan S; Küçücük S; Sahin O; Yigit N; Yildiz Y; Isbir T
In Vivo; 2009; 23(5):767-72. PubMed ID: 19779113
[TBL] [Abstract][Full Text] [Related]
6. Association of cyclin D1 genotype with breast cancer risk and survival.
Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
[TBL] [Abstract][Full Text] [Related]
7. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
8. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers.
Grieu F; Malaney S; Ward R; Joseph D; Iacopetta B
Anticancer Res; 2003; 23(5b):4257-9. PubMed ID: 14666635
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
[TBL] [Abstract][Full Text] [Related]
10. CCND1 and CDKN1B polymorphisms and risk of breast cancer.
Canbay E; Eraltan IY; Cercel A; Isbir T; Gazioglu E; Aydogan F; Cacina C; Cengiz A; Ferahman M; Zengin E; Unal H
Anticancer Res; 2010 Jul; 30(7):3093-8. PubMed ID: 20683061
[TBL] [Abstract][Full Text] [Related]
11. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.
Ceschi M; Sun CL; Van Den Berg D; Koh WP; Yu MC; Probst-Hensch N
Carcinogenesis; 2005 Aug; 26(8):1457-64. PubMed ID: 15845652
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 polymorphism and the risk of endometrial cancer.
Kang S; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 May; 97(2):431-5. PubMed ID: 15863141
[TBL] [Abstract][Full Text] [Related]
13. Her2 genotype and breast cancer progression in Korean women.
An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS
Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849
[TBL] [Abstract][Full Text] [Related]
14. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.
Bedewy AM; Mostafa MH; Saad AA; El-Maghraby SM; Bedewy MM; Hilal AM; Kandil LS
J BUON; 2013; 18(1):227-38. PubMed ID: 23613410
[TBL] [Abstract][Full Text] [Related]
15. Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
Zubor P; Kajo K; Stanclova A; Szunyogh N; Galo S; Dussan CA; Minarik G; Visnovsky J; Danko J
Eur J Cancer Prev; 2008 Feb; 17(1):33-8. PubMed ID: 18090908
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
17. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
Jain M; Kumar S; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Detect Prev; 2007; 31(3):225-32. PubMed ID: 17561354
[TBL] [Abstract][Full Text] [Related]
18. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.
Tao W; Wang C; Han R; Jiang H
Breast Cancer Res Treat; 2009 Mar; 114(2):371-6. PubMed ID: 18438707
[TBL] [Abstract][Full Text] [Related]
19. Association between cyclin D1 (CCND1) polymorphism and gastric cancer risk in Japanese population.
Tahara T; Arisawa T; Shibata T; Yamashita H; Hirata I
Hepatogastroenterology; 2009; 56(93):1232-5. PubMed ID: 19760977
[TBL] [Abstract][Full Text] [Related]
20. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
